Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
NCT ID: NCT05244330
Last Updated: 2022-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1500 participants
OBSERVATIONAL
2021-12-15
2022-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARS-CoV-2 Infection Among Healthcare Workers
NCT05680896
Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
NCT05664919
I VACCIN Hospitalization of COVID-19 Patients
NCT05244343
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
NCT05716425
Topical Antibacterial Agents for Prevention of COVID-19
NCT05449392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Partial vaccination
One dose of vaccine received at least 7 days prior to study enrollment
Full vaccination
Two doses of COVID-19 vaccine received at least 7 days prior to study enrollment
Unvaccinated
No dose of COVID-19 vaccine for at least 7 days prior to study enrollment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clear vaccination information
* Plasma viral load measurements within 24 hours of admission to the hospital
* Performing continuous plasma viral load measurements
* Obtaining informed consent
Exclusion Criteria
* Clinical diagnosis of organ dysfunction or failure before infection
* Long-term use of immunosuppressants or immunodeficiency patients
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Qu, Doctor
Role: STUDY_DIRECTOR
First Affiliated Hospital Xi'an Jiaotong University
Guoliang Li, Doctor
Role: STUDY_DIRECTOR
First Affiliated Hospital Xi'an Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Xian JiaotongUniversity
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XJTU1AF2022LSK-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.